Clotrimazole shortage: What providers and prescribers need to know in 2026

Clotrimazole Supply in 2026: A Provider's Overview

Clotrimazole remains a foundational antifungal in clinical practice — prescribed across primary care, dermatology, OB/GYN, oncology, and transplant medicine. While the over-the-counter topical and vaginal formulations enjoy broad availability, the prescription oral troche has experienced intermittent supply tightness in recent years, prompting many providers to proactively consider alternatives and patient access strategies.

This article provides an evidence-based update on Clotrimazole supply, clinical substitution options, and practical tools to support your patients.

Current Supply Status

As of March 2026, the FDA has not listed Clotrimazole on its active drug shortage database. However, the clinical reality is more nuanced:

• OTC topical and vaginal forms: Widely available through multiple manufacturers and distribution channels. No supply concerns.
• Oral troches (10 mg): Produced by a limited number of generic manufacturers. Intermittent spot shortages occurred in 2023-2024 due to production disruptions at select facilities. Supply has largely stabilized but remains susceptible to regional variability.
• Lotrisone (Clotrimazole/Betamethasone): Generic availability varies; brand supply is generally stable.

Providers should be aware that absence from the FDA shortage list does not guarantee universal pharmacy-level availability, particularly for the oral troche formulation.

Clinical Impact and Patient Populations at Risk

Patients most affected by Clotrimazole troche supply disruptions include:

• Hematopoietic stem cell transplant (HSCT) recipients receiving antifungal prophylaxis
• Solid organ transplant patients on chronic immunosuppression
• Oncology patients undergoing chemotherapy or radiation to the head/neck
• HIV/AIDS patients with recurrent oropharyngeal candidiasis
• Patients on chronic corticosteroid therapy (inhaled or systemic)

For these populations, interruption of antifungal prophylaxis or treatment can lead to clinically significant morbidity. Proactive identification of supply issues and timely substitution are essential components of patient care.

Clinical Alternatives: Evidence-Based Substitution

For Oropharyngeal Candidiasis (Thrush)

When Clotrimazole troches are unavailable, the following evidence-based alternatives should be considered:

Nystatin Oral Suspension (100,000 units/mL)

• Dose: 4-6 mL swish-and-swallow, 4 times daily for 7-14 days
• Advantages: Minimal systemic absorption, negligible drug interactions (critical for transplant patients on Tacrolimus/Sirolimus), widely available
• Limitations: Taste tolerability, frequent dosing, lower efficacy in some studies compared to azoles
• IDSA recommendation: Mild disease, first-line alternative

Fluconazole (Diflucan)

• Dose: 200 mg loading dose, then 100-200 mg daily for 7-14 days
• Advantages: Systemic efficacy, once-daily dosing, well-studied in immunocompromised populations
• Limitations: CYP2C9/CYP3A4 interactions (Tacrolimus, Warfarin, Statins), hepatotoxicity risk, QT prolongation potential, teratogenic
• IDSA recommendation: Moderate-to-severe disease, preferred for immunocompromised patients

Miconazole Buccal Tablet (Oravig, 50 mg)

• Dose: One tablet applied to the gum once daily for 14 days
• Advantages: Localized delivery, once-daily application
• Limitations: Limited availability, higher cost, may adhere poorly in patients with xerostomia

For Dermatophyte and Cutaneous Candidal Infections

OTC substitutions for Clotrimazole topical include:

• Miconazole 2% cream — equivalent efficacy for most cutaneous fungal infections
• Terbinafine 1% cream (Lamisil AT) — superior mycological cure rates for dermatophyte infections; shorter treatment duration (1-2 weeks)
• Ketoconazole 2% cream — prescription; preferred for pityriasis versicolor

For Vulvovaginal Candidiasis

• Miconazole (Monistat) — OTC, multiple treatment durations available (1, 3, or 7 day)
• Fluconazole 150 mg single oral dose — convenient; contraindicated in pregnancy
• Terconazole — prescription vaginal cream/suppository; may be effective in azole-resistant cases

Important Drug Interaction Considerations

A critical consideration when prescribing Clotrimazole oral troches — and one frequently underappreciated — is the significant drug interaction with immunosuppressive agents:

• Tacrolimus: Clotrimazole troches inhibit intestinal CYP3A4 and P-glycoprotein, significantly increasing Tacrolimus trough levels. Published case reports document nephrotoxicity and transplant rejection events. Close monitoring of Tacrolimus levels is warranted when initiating or discontinuing Clotrimazole troches.
• Sirolimus: Similar mechanism; documented cases of supratherapeutic levels and acute kidney injury.
• Cyclosporine: Potential for increased levels via CYP3A4 inhibition.

When switching from Clotrimazole troches to an alternative, consider the interaction profiles of substitutes as well. Nystatin has minimal drug interactions and may be preferred in the transplant population. Fluconazole, while more efficacious, has more significant CYP-mediated interactions.

For detailed interaction data, see our reference article on Clotrimazole drug interactions.

Formulary and Access Strategies

To mitigate the impact of supply disruptions on your patients:

• Maintain therapeutic alternatives on formulary. Ensure Nystatin oral suspension and Fluconazole are readily available as substitutes.
• Communicate proactively with pharmacy. Hospital and clinic pharmacies should monitor Clotrimazole troche supply through wholesaler dashboards and ASHP/FDA shortage databases.
• Pre-authorize alternatives. For high-risk patients (transplant, oncology), consider documenting preferred alternative agents in the medical record to expedite substitution.
• Leverage patient-facing tools. Direct patients to MedFinder for Providers to help them locate pharmacies with Clotrimazole in stock.

Helping Your Patients Navigate Supply Issues

When patients report difficulty finding Clotrimazole:

1. Verify the formulation needed — OTC cream vs. prescription troche. Many patients may not realize OTC options exist for non-oral indications.
2. Offer to send the prescription to an alternative pharmacy or mail-order service.
3. Provide patient education resources. Share links to patient-facing articles such as our guide to finding Clotrimazole in stock and alternatives to Clotrimazole.
4. Consider cost barriers. Prescription Clotrimazole troches can cost $50-$120 without insurance. Discount coupon programs can reduce costs to $5-$15. Direct patients to our savings guide.

For a comprehensive guide on supporting patients through supply issues, see our provider resource on how to help patients find Clotrimazole in stock.

Resources for Providers

• MedFinder for Providers — Help patients locate medications in stock at nearby pharmacies
• FDA Drug Shortages Database — Official shortage tracking
• ASHP Drug Shortage Resource Center — Clinical alternatives and management strategies
• IDSA Clinical Practice Guidelines for Candidiasis — Evidence-based treatment recommendations

The Bottom Line

Clotrimazole remains a safe, effective, and generally accessible antifungal. While the oral troche form may experience intermittent supply challenges, OTC formulations are widely available. Providers should maintain awareness of alternative agents, monitor their patients' ability to access medications, and leverage tools like MedFinder to support timely treatment. Proactive communication with pharmacy teams and patients is the most effective strategy for managing supply variability.